During the 1980's much has been learnt about early breast cancer and several clear guidelines have emerged to assist in the management of such patients. It is now clear that conservative surgery such as lumpectomy or quadrantectomy followed by radiotherapy gives the same survival as more radical surgery (Fisher et al., 1985; Veronesi et al., 1990 ; Van de Schueren et al., 1988) . Following publication of the recent overview of adjuvant therapy trials it is also now clear that adjuvant chemotherapy can significantly prolong the survival of women younger than 50 years at the time of diagnosis and that adjuvant tamoxifen has a similar effect in those older than 50 (Early Breast Cancer Trialists Collaborative Group, 1988) .
Axillary nodal status is generally accepted to be the most important prognostic factor in patients with operable breast cancer. In the overview 73% of the women in the chemotherapy studies and 57% of those in the tamoxifen studies were node positive. Detailed analyses of outcome amongst patients with positive and negative axillary nodes are awaited but, the initial report suggests that although the proportional reductions in mortality amongst women with and without axillary nodal involvement appear to be similar, this reduction in mortality does not achieve conventional statistical significance for either form of adjuvant treatment in an analysis restricted to patients with negative axillary nodes.
The prognosis of patients who present with operable breast cancer is extremely variable and tremendous efforts have been made over the years to identify additional factors which may be measured at the time of presentation which will give an accurate indication as to the likely prognosis of a given patient, and which may then be used to assist in decision making regarding the choice of treatment for that patient. Such work has led to the development of prognostic indices.
In the UK the best known of these indices is that derived in Nottingham (Haybittle et al., 1982; Todd et al., 1987) tion (1988) which showed the effect of tamoxifen to be independent of nodal status, menopausal status and hormone receptor status. Whilst this trend is not to be encouraged, it represents a real phenomenon perhaps fuelled by a wish to avoid morbidity such as arm oedema which may be associated with axillary surgery particularly if combined with radiotherapy. There is therefore a clear need for the development of accurate prognostic indices which do not involve axillary surgery and which will also help to identify the 30% of patients who still relapse and die within 10 years despite being pathologically node negative (Craig Henderson et al., 1989) . It would also be extremely useful to be able to reliably identify the group of patients who relapse and die very quickly, for whom it may be appropriate to consider more intensive therapies.
Hunts for new prognostic factors have considered variables such as oestrogen receptor (ER) status (Fisher et al., 1988) or the use of flow cytometry to determine ploidy and S-phase fraction (Clark et al., 1989; Fallenius et al., 1988) . Publication of preliminary papers by Sainsbury et al. (1987) and by Slamon et al. (1987) showing that patients with over expression of the epidermal growth factor receptor (EGFR) or amplification of the c-erbB-2 oncogene had a poor prognosis, has drawn attention to the evaluation of oncogenes and growth factors as potential prognostic markers.
The most studied oncogene in breast cancer is c-erbB-2 and papers addressing its biological or clinical significance from at least 26 different groups can be found in the literature. This gene which is also known as neu or HER-2 or HER-2/neu codes for a putative growth factor receptor of the tyrosine kinase family which is closely related to, but distinct from EGFR (Coussens et al., 1985) . The ligand for the c-erbB-2 protein is as yet unknown, although two candidate ligands have recently been identified (Lippman et al., Data presented at UICC 15th International Cancer Congress, Hamburg 1990) .
In this edition of the British Journal of Cancer, four further papers concerning the prognostic significance of c-erbB-2 expression are published. Three of these papers are particularly notable: two because they are amongst the largest systematically collected series in the literature reporting data on 497 and 462 patients respectively (Lovekin et al., 1991; Winstanley et al., 1991) ; the third paper (Gullick et al., 1991) is notable because it reports the results of a form of metaanalysis which combines the results of three relatively small previously published studies (Gusterson et al., 1988; Barnes et al., 1988; Wright et al., 1989a) to produce a much more statistically robust conclusion than could be derived from any one of the studies alone. The fourth papers reports the results of a moderately sized study (172 patients) and is interesting because in addition to reporting the association between c-erbB-2 expression and conventional prognostic factors it also examines the association of its expression with S-phase fraction as a marker of tumour proliferation as measured by DNA flow cytometry (O'Reilly et al., 1991) .
All four groups used the polyclonal antiserum 21N as produced by Gullick et al. (1987) , to stain archival formalin fixed paraffin embedded breast tumours, and all considered tumours expressing moderate to strong membrane staining to be positive for c-erbB-2. The percentage of tumours expressing the oncogene was consistently in the upper teens or low twenties which is entirely consistent with the results of other published studies using monoclonal or polyclonal antibodies on formalin fixed paraffin embedded sections (Thor et al., 1989; Paik et al., 1990; Walker et al., 1989 ; Van de Vivjer et al., 1988; Richner et al., 1990) .
Much of the previously published data concerns the associations between c-erbB-2 expression and conventional prognostic factors. The results of these studies have varied considerably but several studies have found consistent results with respect to certain prognostic factors. The original study reported by Slamon et al. (1987) showed a positive association between c-erbB-2 expression and the number of involved axillary nodes, this finding has not been generally reproducible but finds some support in three other studies (Tandon et al., 1989; Guerin et al., 1989; May et al., 1990 ) and indirectly in the study by Zhou et al. (1989) ship between c-erbB-2 expression and other markers of differentiation. Ploidy has previously been investigated by two groups neither of whom found any significant association (Tavassoli et al., 1989; Ro et al., 1989) At least 20 other groups have now published data concerning the prognostic significance of c-erbB-2, of these only four groups have failed to find a prognostic effect of c-erbB-2 in at least one sub group (Zhou et al., 1989; Ali et al., 1988; Gusterson et al., 1988; Barnes et al., 1988) . Van 1990; Walker et al., 1989; Tsuda et al., 1989) . All of these papers show that the prognostic effect of c-erbB-2 is maintained in multivariate analysis. If the details of those studies which show no, or only a limited, prognostic effect of c-erbB-2 are compared to those where there is an overall prognostic effect it is apparent that significant prognostic effects tend to be seen in the larger studies. This is borne out by the result of the studies published in this edition of the Journal three of which showed an overall effect of c-erbB-2 on prognosis and all of these studies contained more than 450 patients. Of the papers published in this edition of the Journal, only that from Gullick et al. shows a significant overall association between c-erbB-2 expression and both recurrence and survival which is confirmed in multivariate anlaysis. This paper lends further support to the hypothesis that some of the apparent differences in the prognostic significance of c-erbB-2 expression between groups may simply be a function of study size. In their overview they include two studies which individually showed no significant prognostic effect of c-erbB-2 expression, although both showed a non significant trend towards poor prognosis for patients with tumours positive for c-erbB-2 (Gusterson et al., 1988; Barnes et al., 1988) . However, when considered together with a third study, which had individually shown an independent prognostic effect in terms of both relapse and survival (Wright et al., 1989a ) the strong independent prognostic effect for the group as a whole was confirmed and shown to be equivalent in both node positive and node negative patients.
Of the other two large studies published in this edition of the Journal, both restrict their analyses to survival and both report a highly significant association between c-erbB-2 expression and poor survival. In the Lovekin paper c-erbB-2 is found not to be an independent prognostic indicator in a model which also considers axillary nodal stage, size of primary tumour, and histological grade. However, in this study there was a very strong association between c-erbB-2 status and grade and when grade was omitted from the multivariate analysis c-erbB-2 status became an independent prognosticator. In the Winstanley paper multivariate analysis showed c-erbB-2 receptor status to be an independent prognosticator alongside axillary nodal status and primary tumour size, the effect of histological grade was however not tested in this study.
Other studies have shown a significant effect of c-erbB-2 expression in the overall survival analysis but not in the recurrence free analysis (Paik et al., 1990; Parkes et al., 1990 ; Van de Vivjer et al., 1988) , but only that by Paik shows c-erbB-2 expression to be independent prognostic significance on multivariate analysis.
Most groups have examined the prognostic significance of c-erbB-2 expression in sub-groups defined by conventional prognostic indicators. The results are again conflicting. Some papers find the prognostic effect of c-erbB-2 expression to be restricted to the node positive subset (Slamon et al., 1989; Tandon et al., 1989; Borg et al., 1990 ) and similar results are described by O'Reilly et al. who, however, show that the independent prognostic effect of c-erbB-2 expression was restricted to the recurrence free survival analysis. Other groups have made the potentially very important observation that there is a significant prognostic effect of c-erbB-2 expression in groups that would generally be considered to have a good prognosis. This includes the node negative subset where an association between c-erbB-2 expression and poor survival is described in papers by Wright et al. (1989a) and Ro et al. (1989) . Paik et al. (1990) demonstrated that the maximum prognostic effect of c-erbB-2 expression, in terms of survival, was seen in those patients who had well differentiated tumours, particularly in those who were also node negative. A similar effect was noted in a study of 79 node negative patients (Richner et al., 1990) where although there was no overall association between c-erbB-2 expression and overall survival, such an association was found in the ER positive subset (P = 0.001). Wright et al. (1989a) also found that the prognostic effect of c-erbB-2 expression was stronger in ER positive than ER negative tumours and also stronger in EGFR negative tumours than EGFR positive tumours. May et al. (1989) (May et al., 1990) c-erbB-2 receptor expression is equivalent in node positive and in node negative patients and make the extremely important point that in order to reliably demonstrate the prognostic effect of c-erbB-2 expression in the node negative subset large numbers of patients are required. This is because c-erbB-2 is expressed relatively infrequently and because node negative patients have a much better prognosis than node positive patients and therefore relapse and die less frequently. Many more node negative cases are therefore required to obtain similar statistical significance because statistical power is dependent upon the number of events in the study. It is not clear how c-erbB-2 expression exerts its prognostic effect and is may be simply that tumour cells positive for c-erbB-2 have a growth advantage over cells negative for this oncogene. There may however also be some relationship between c-erbB-2 expression and responsiveness to treatment. A number of studies show that the prognostic effect of c-erbB-2 expression is stronger for survival than it is for recurrence (O'Reilly et al., 1991; Gullick et al., 1991; Wright et al., 1989a; Paik et al., 1990; Ro et al., 1989; Parkes et al., 1990; Tsuda et al., 1989; Van de Vivjer et al., 1988) . This implies that part of the prognostic effect of c-erbB-2 expression is exerted during the period after recurrence, a period when the patients are likely to be receiving chemo-or hormonal therapy. Some preliminary results published in abstract form lend some support to this hypothesis. Fifty-nine patients with operable breast cancer who relapsed after primary surgical management alone were all treated with tamoxifen, 19 patients responded, 18 of whom (95%) had tumours that were negative for c-erbB-2; of the non responders, only 28 of the 40 (70%) were negative for c-erbB-2 (P<0.07). The 13 patients who were positive for c-erbB-2 had a particularly poor prognosis and 12 (92%) showed evidence of disease progression within 6 months of starting tamoxifen compared to only 31 of 46 (67%) who were negative for c-erbB-2, post relapse survival was also significantly shorter for this group of patients (P<0.01) (Wright et al., 1989b) .
In summary, c-erbB-2 expression appears to be a useful addition to the prognostic armamentarium. There is evidence to suggest that its expression is more frequent in tumours of advanced stage and in tumours that are more poorly differentiated. These associations are however far from absolute as is shown by the marked difference in results between published papers. Because the oncogene is expressed relatively infrequently, larger studies such as those published in this edition of the Journal are required to clearly demonstrate its prognostic significance, and this is particularly the case when subset analyses are performed looking at those groups which would be considered to have a good prognosis by conventional prognostic indicators.
One major limitation of the studies published to date is that they are all retrospective and the patients included are therefore limited by the availability of material and the analyses limited by the availability of information regarding other prognosticators. Large prospective studies are now required to fully assess the prognostic significance of this interesting new biological variable. Such studies should also be able to provide information as the whether c-erbB-2 expression can predict responsiveness to chemo-or hormonal-therapy. Further work is also required to assess the relative strength of c-erbB-2 as a prognostic marker relative to other promising new markers such as the proteases Cathepsin D (Spyratos et al., 1989; Thorpe et al., 1989; Tandon et al., 1990 ) and urokinase type plasminogen activator antigen (Janicke et al., 1989) as well as other markers such as the NM23 gene (Bevilacqua et al., 1989) and mutant p53 (Harris et al., 1990) .
